In a 78-year-old woman taking fluoxetine 10 mg daily and mirtazapine 15 mg nightly who is markedly drowsy and has hyponatraemia (serum sodium 133 mmol/L), mildly elevated aspartate aminotransferase (AST 43 U/L), and severe thrombocytopenia (platelet count 31 ×10⁹/L), what is the appropriate initial management?

Immediate Management: Discontinue Both Antidepressants and Investigate Urgently

The most critical action is to immediately discontinue both fluoxetine and mirtazapine due to severe thrombocytopenia (platelet count 31 ×10⁹/L) and symptomatic hyponatremia (sodium 133 mmol/L with marked drowsiness), as both medications are likely contributing to these life-threatening complications.

Primary Concerns Requiring Urgent Action

1. Severe Thrombocytopenia (Platelet 31 ×10⁹/L)

Both fluoxetine and mirtazapine must be stopped immediately due to the critical platelet count, which places the patient at high risk for spontaneous bleeding:

• Fluoxetine is directly implicated in drug-induced thrombocytopenia, with documented cases showing platelet decline to levels as low as 34 ×10³/µL during SSRI therapy 1. The mechanism involves immune dysregulation and direct platelet effects.

• Mirtazapine can cause bone marrow suppression and hematologic abnormalities 2, though less commonly reported than with SSRIs.

• At platelet counts <50 ×10⁹/L, there is significant bleeding risk requiring immediate intervention and hematology consultation.

2. Symptomatic Hyponatremia with Drowsiness

The combination of sodium 133 mmol/L with marked drowsiness represents symptomatic hyponatremia requiring urgent management:

Both antidepressants are contributing:

• Mirtazapine has a documented 3.26% incidence of hyponatremia (95% CI 3.06-3.45%), with SIADH as the most probable mechanism 3. Cases occur within an average of 34 days, with mean sodium nadirs of 117 mEq/L 4.

• Fluoxetine (SSRI) carries well-established hyponatremia risk, with documented cases of severe SIADH causing sodium levels as low as 105 mmol/L 5.

• The combination of two serotonergic agents (fluoxetine + mirtazapine) likely has additive effects on SIADH development 2.

• Elderly patients (78 years old) are at markedly increased risk for antidepressant-induced hyponatremia 2, 6.

Immediate Management Algorithm

Step 1: Discontinue Both Antidepressants Immediately

• Stop fluoxetine 10 mg daily
• Stop mirtazapine 15 mg nightly
• Do not taper given the severity of complications—the risk of continued exposure outweighs discontinuation syndrome risk 2

Step 2: Urgent Laboratory and Clinical Assessment

• Complete blood count with differential to assess for other cytopenias
• Peripheral blood smear to evaluate platelet morphology and rule out pseudothrombocytopenia
• Serum osmolality, urine osmolality, and urine sodium to confirm SIADH
• Thyroid function (TSH, free T4) and morning cortisol to exclude other causes of hyponatremia 7
• Liver function tests beyond AST (ALT, alkaline phosphatase, bilirubin, albumin) to evaluate the mildly elevated AST (43 U/L)
• Renal function (creatinine, BUN)

Step 3: Hyponatremia Management

Given symptomatic hyponatremia (drowsiness) at sodium 133 mmol/L:

• Fluid restriction to <1000 mL/day 8, 7
• Monitor sodium levels daily initially
• Avoid rapid correction: target increase of 4-6 mEq/L per 24 hours, not exceeding 8 mEq/L per 24 hours to prevent osmotic demyelination syndrome 8
• Consider hospitalization if drowsiness worsens or sodium continues to decline 7

Step 4: Thrombocytopenia Management

• Hematology consultation for platelet count 31 ×10⁹/L
• Avoid antiplatelet agents (aspirin, NSAIDs) and anticoagulants
• Bleeding precautions: avoid intramuscular injections, minimize trauma risk
• Monitor platelet count every 2-3 days initially after drug discontinuation
• Expected recovery timeline: 7-10 days after stopping the offending agent 1

Step 5: Evaluate AST Elevation (43 U/L)

The mildly elevated AST requires investigation but is less urgent:

• Rule out drug-induced hepatotoxicity from antidepressants 9
• Consider non-hepatic causes: cardiac muscle damage, skeletal muscle damage, or hematologic disorder 10
• Check CPK to evaluate for rhabdomyolysis (mirtazapine can cause muscle rigidity)
• Repeat liver enzymes in 1 week after drug discontinuation

Common Pitfalls to Avoid

1. Do not restart either antidepressant until platelet count normalizes (>150 ×10⁹/L) and hyponatremia fully resolves
2. Do not use vaptans (vasopressin antagonists) in this elderly patient—they are associated with hepatic injury and mortality in vulnerable populations 7, 11
3. Do not correct sodium too rapidly—elderly patients with chronic hyponatremia are at highest risk for osmotic demyelination syndrome 8
4. Do not overlook the additive risk of combining two serotonergic agents in elderly patients

Future Antidepressant Selection

When depression treatment is resumed after laboratory normalization:

• Avoid all SSRIs (fluoxetine, sertraline, etc.) due to higher hyponatremia risk (odds ratios 1.5-21.6) and thrombocytopenia risk 6
• Avoid SNRIs (venlafaxine) due to similar hyponatremia risk (incidence 0.08-70%) 6
• Avoid mirtazapine due to documented moderate hyponatremia risk 3, 6
• Consider bupropion as first-line alternative—insufficient evidence of hyponatremia association 6
• Monitor sodium levels weekly for first month with any new antidepressant in this high-risk patient 2

Expected Recovery Timeline

• Hyponatremia: Mean recovery time 11 days after stopping mirtazapine 4; may be faster with combined discontinuation
• Thrombocytopenia: Recovery typically within 7-10 days after stopping fluoxetine 1
• Clinical improvement: Drowsiness should improve within days as sodium normalizes

2, 1, 3, 4, 6, 5